12935_2018_645_MOESM3_ESM.png (198.46 kB)
MOESM3 of A drug screening assay on cancer cells chronically adapted to acidosis
figure
posted on 2018-09-25, 05:00 authored by Paola Pellegrini, Jason Serviss, Thomas Lundbäck, Nicolo Bancaro, Magdalena Mazurkiewicz, Iryna Kolosenko, Di Yu, Martin Haraldsson, Padraig DâArcy, Stig Linder, Angelo MilitoAdditional file 3: Figure S3. (A) HCT116 cells were treated with VP for the indicated time points and the expression of SQSTM1 of different MW was assessed by WB. (B) HCT116 and AA-HCT116 cells were treated VP and the expression of mTOR was analysed by WB. Cells were also untreated (C) or treated with EBSS (S). (C) HCT116 and AAHCT116 cells were treated VP and the expression of GRP78 was analysed by WB. (D) Analysis of UPS-related GO terms and associated P values. (E) HCT116 cells were treated with Bortezomib or Verteporfin for 4 h combining light (L) and darkness (D) during treatment of the cells and protein extraction. The accumulation of polyubiquitinated proteins was analysed by WB.